[Skip navigation]FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Search Powered by Google
 

Consumer Information Sheet
Fondaparinux Sodium (marketed as Arixtra)

Arixtra Injection
Brand Name: Arixtra
Active Ingredient:   fondaparinux sodium
Strength(s): 2.5 mg/0.5 mL
Dosage Form(s):   Sucutaneous Injection
Company Name:    Fonda BV
Availability:         Prescription only, professional use only
*Date Approved by the FDA:   December 7, 2001
*Approval by FDA does not mean that the drug is available for consumers at this time.

What is Arixtra used for? 

Arixtra is used to reduce the risk of blood clots in the deep veins of the legs and thighs.  These clots may break off and travel to the lungs (pulmonary embolism).  Patients at risk for these complications include those undergoing:

  • hip fracture surgery,
  • hip replacement surgery,
  • knee replacement surgery,
  • abdominal surgery who are already at risk of blood clot complications

Arixtra also is used with warfarin to treat:

·         blood clots in the veins

·         blood clots  that have broken off and traveled to the lungs (pulmonary embolism) when the patient is first treated in the hospital

Who should not be given Arixtra?

Arixtra should not be given to patients who: 

  • have severe kidney problems
  • weigh less than 110 pounds (50kg)
  • have bleeding anywhere
  • have a heart infection (bacterial endocarditis)
  • have a history of Arixtra causing the blood to have low platelets (thrombocytopenia)
  • are allergic to Arixtra or to any of the ingredients in Arixtra

Tell your healthcare provider if you have any of these conditions.

Special Warning(s) with Arixtra:

Arixtra and other medicines like it can cause bleeding into the spine when used in patients who have received epidural or spinal anesthesia, or any spinal injection. Bleeding in the spine can cause long term or permanent paralysis. 

Arixtra, like other medicines that prevent the blood from clotting, is given with extreme caution to people who have conditions that have an increased risk of bleeding, such as: 

  • bleeding disorders 
  • ulcerative colitis and other bleeding disorders in the stomach and intestines 
  • bleeding into the brain (hemorrhagic stroke) 
  • recent brain, spinal, or eye surgery 
  • taking other medicines that prevent the blood from clotting 

General Precautions with Arixtra:

Certain other medicines can increase the risk of bleeding with Arixtra. Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially, tell your health care provider if you are taking: 

  • blood thinners 
  • aspirin 
  • non-steroidal anti-inflammatory drugs such as ibuprofen (Motrin) or naproxen sodium (Naprosyn or Aleve) 

What should I tell my doctor or healthcare provider?

Tell your healthcare provider if you have:

  • bleeding problems, any recent bleeding, or if you bleed easily
  • high blood pressure
  • a recent stomach ulcer
  • eye problems due to diabetes
  • kidney problems
  • had a stroke

What are some possible side effects of Arixtra? (This list is NOT a complete list of side effects reported with Arixtra. Your healthcare provider can discuss with you a more complete list of side effects.)

The most common side effect with Arixtra is bleeding.

For more detailed information about Arixtra, ask your healthcare provider.

Link to Arixtra's label

Back to Drug Index

.

PDF requires the free Adobe Acrobat Reader

Back to Top     Back to Drug Index

Date created:  November 22, 2002, Updated:  7/25/2005, 8/2005

horizonal rule